Saikosaponin B2 Suppresses Inflammatory Responses Through IKK/IκBα/NF-κB Signaling Inactivation in LPS-Induced RAW 264.7 Macrophages.
Animals
Anti-Inflammatory Agents
/ pharmacology
I-kappa B Proteins
/ metabolism
Inflammation
/ drug therapy
Lipopolysaccharides
/ pharmacology
Macrophages
/ drug effects
Mice
NF-kappa B
/ metabolism
Oleanolic Acid
/ analogs & derivatives
RAW 264.7 Cells
Saponins
/ pharmacology
Signal Transduction
/ drug effects
IKK
NF-κB
macrophage
saikosaponin B2
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
27
9
2018
medline:
4
6
2019
entrez:
26
9
2018
Statut:
ppublish
Résumé
Bupleurum falcatum (Umbelliferae) have been widely used to treat inflammatory diseases as traditional medicines in East Asian region. Although saikosaponins are main bioactive molecules of B. falcatum, there is little information on bioactivity of saikosaponin B
Identifiants
pubmed: 30251218
doi: 10.1007/s10753-018-0898-0
pii: 10.1007/s10753-018-0898-0
doi:
Substances chimiques
Anti-Inflammatory Agents
0
I-kappa B Proteins
0
Lipopolysaccharides
0
NF-kappa B
0
Saponins
0
Oleanolic Acid
6SMK8R7TGJ
saikosaponin D
UR635J3F00
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-353Subventions
Organisme : National Research Foundation of Korea
ID : 2017R1A5A2014768
Organisme : National Research Foundation of Korea
ID : NRF-2017R1A6A3A11031647
Références
J Biol Chem. 2000 Aug 4;275(31):23814-24
pubmed: 10781614
Annu Rev Immunol. 2000;18:621-63
pubmed: 10837071
J Clin Invest. 2001 Jan;107(2):135-42
pubmed: 11160126
Br J Pharmacol. 2001 Nov;134(5):1055-65
pubmed: 11682454
Cell. 2002 Apr;109 Suppl:S81-96
pubmed: 11983155
EMBO J. 2003 Mar 17;22(6):1313-24
pubmed: 12628924
Prog Lipid Res. 2004 Jan;43(1):3-35
pubmed: 14636669
Proc Am Thorac Soc. 2005;2(4):386-90; discussion 394-5
pubmed: 16267367
Cell Signal. 2006 Dec;18(12):2238-51
pubmed: 16806820
Trends Pharmacol Sci. 2006 Aug;27(8):399-401
pubmed: 16815559
Eur J Pharmacol. 2006 Sep 18;545(2-3):192-9
pubmed: 16899239
Biochem Pharmacol. 2006 Oct 30;72(9):1102-13
pubmed: 16930560
Oncogene. 2007 May 14;26(22):3214-26
pubmed: 17496917
Planta Med. 1991 Dec;57(6):511-4
pubmed: 1818339
Planta Med. 1991 Dec;57(6):555-9
pubmed: 1818348
Eur J Pharmacol. 2008 Apr 14;584(1):175-84
pubmed: 18295200
Pharmacol Rev. 1991 Jun;43(2):109-42
pubmed: 1852778
J Reprod Immunol. 2008 Oct;79(1):50-7
pubmed: 18550178
Comp Immunol Microbiol Infect Dis. 2010 Sep;33(5):443-54
pubmed: 19732955
Int Immunopharmacol. 2010 Aug;10(8):943-50
pubmed: 20546946
Br J Pharmacol. 2011 Sep;164(1):145-58
pubmed: 21434881
J Cell Biochem. 2011 Dec;112(12):3594-603
pubmed: 21809372
Mol Med Rep. 2012 Mar;5(3):637-44
pubmed: 22159471
Int Immunopharmacol. 2012 Sep;14(1):121-6
pubmed: 22728095
Food Chem. 2012 Dec 1;135(3):967-75
pubmed: 22953812
Front Immunol. 2014 Feb 25;5:71
pubmed: 24611065
Neurol Sci. 2014 Nov;35(11):1763-8
pubmed: 24873902
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Exp Biol Med (Maywood). 2015 Jul;240(7):946-54
pubmed: 25361770
J Hepatol. 2015 Mar;62(3):541-8
pubmed: 25450204
Int J Mol Med. 2015 Apr;35(4):1126-32
pubmed: 25672367
Chem Biol Interact. 2015 Jun 25;235:85-94
pubmed: 25913072
Int Immunopharmacol. 2015 Sep;28(1):399-408
pubmed: 26118633
Int J Immunopathol Pharmacol. 2015 Sep;28(3):296-307
pubmed: 26130747
Sci Rep. 2015 Oct 30;5:15946
pubmed: 26515683
Oncotarget. 2015 Dec 15;6(40):42541-56
pubmed: 26637810
Cells. 2016 Mar 18;5(1):null
pubmed: 26999213
Oncotarget. 2016 Aug 2;7(31):48995-49007
pubmed: 27285988
BMC Cancer. 2016 Jul 26;16:532
pubmed: 27461108
Int Immunopharmacol. 2016 Nov;40:146-155
pubmed: 27591413
Oncogenesis. 2016 Dec 12;5(12):e279
pubmed: 27941930
Oncol Res. 2017 Jan 26;25(2):233-239
pubmed: 28277195
Nutr Cancer. 2017 Apr;69(3):505-511
pubmed: 28287317
Front Pharmacol. 2017 Aug 18;8:547
pubmed: 28868036
PLoS One. 2018 Jun 11;13(6):e0198943
pubmed: 29889899